Clinical Trials
12 trialsNCT04877522 2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT00756509 2026-01-20
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Novartis
Phase 4 Completed
NCT01735955 2024-02-08
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Completed
NCT02546674 2022-07-22
NILOdeepR
Novartis
Phase 4 Completed
NCT00980018 2021-07-01
MACS0999
Novartis
Phase 4 Completed
NCT01131325 2021-05-20
MACS1148
Novartis
Phase 4 Terminated
NCT01605981 2017-04-20
MACS1881
Novartis
Phase 4 Withdrawn
NCT01061177 2017-02-24
'MACS1252
Novartis
Phase 4 Completed
NCT00786812 2017-02-23
MACS0439
Novartis
Phase 4 Completed
NCT01368523 2016-11-16
Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial
Novartis
Phase 4 Completed
NCT01043874 2016-04-08
MACS0911
Novartis
Phase 4 Completed
NCT01227577 2016-02-08
MACS1428
Novartis
Phase 4 Completed